The disclosure is directed to fibrous structures finished with active pharmaceutical ingredients, as well as methods of their manufacturer and use.

The present invention provides an external preparation composition comprising lactic acid salt of lidocaine consisting of lidocaine and a lactic acid ingredient and diclofenac or a salt thereof wherein the lactic acid ingredient is lactic acid and an alkali metal salt or alkaline earth metal salt of lactic acid, and an external preparation which exhibits higher transdermal absorbability of both lidocaine and diclofenac and the skin permeability suitable for clinical use, and enhances the storage stability and safety of the preparation to allow the long-term storage.

A penile implant enhancement device and method is provided. The penile implant device comprises an elongated cylindrical sleeve that is configured to encircle a shaft of a penis and an external layer. The elongated cylindrical sleeve is defined by one or more edges, surfaces, or layers, including a proximal edge, a distal edge, a first side, a second side, a top surface, and a bottom surface, and the external layer is configured to cover the one or more edges, surfaces, or layers of the sleeve to form one or more covered edges, surfaces, or layers. The covered edges, surfaces, or layers are configured to align with the penis. The method comprises the steps of administering one or more anesthetic agents; cutting a transverse incision above the pubic symphysis; clamping a lower edge of the transverse incision; dissection through the one or more layers of subcutaneous tissue to expose tunica albuginea; everting the penis; creating a pocket between the tunica albuginea and the skin; providing the aforementioned penile implant device; suturing the covered edges, surfaces, or layers to the penis; trimming the external layer, reverting the penis; and closing the transverse incision.

Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

The invention provides azaspiro[4.5]decane derivatives of Formula (A): and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, wherein A.sup.1, X, A.sup.2, Rr, R.sup.2′, W.sup.1, W.sup.2, R.sup.3′, R.sup.4′, a, and b are defined in the disclosure. The invention also provides compounds of Formulae I, and B-G, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof. Further, the invention provides use of the compounds of Formulae A-G and I, and the pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, to treat pain. In certain embodiments, Compounds of the Disclosure are useful for treating a disorder responsive to blockade of one or more sodium channels. ##STR00001##

A method for applying a regional block of the articular sensory branch of femoral (FN), obturator (ON) and accessory obturator nerves (AON) comprising injection of an anesthetic at a single needle entry point into a these nerves anatomical sites. Another aspect of this technology is a kit for performing this method.

A method for applying a regional block of the articular sensory branch of femoral (FN), obturator (ON) and accessory obturator nerves (AON) comprising injection of an anesthetic at a single needle entry point into a these nerves anatomical sites. Another aspect of this technology is a kit for performing this method.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days. The assembly further includes a fixation portion coupled to the depot and configured to facilitate attachment of the depot assembly to tissue at or adjacent to the treatment site.

A multifunctional microstructure patch is provided. The multifunctional microstructure patch, according to one embodiment of the present invention, comprises: a base layer having an opening part formed in the center thereof; a plurality of microstructures formed on one surface of the base layer and comprising a first drug; and a cover layer detachably bonded on the other surface of the base layer along the periphery of the opening part, and formed so as to cover the opening part.